Slingshot members are tracking this event:
European Medicines Agency Accepts Bristol-Myers Squibb's (BMY) Marketing Application for New Use of Opdivo in Locally Advanced Unresectable or Metastatic Urothelial Carcinoma
Slingshot Insights Explained
Sep 20, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Opdivo, Marketing Application, European Medicines Agency, Locally Advanced Unresectable, Metastatic Urothelial Carcinoma